{"entity":{"id":"sandra-dangelo","kind":"person","name":"Sandra P. D'Angelo","aka":[],"tldr":"Led SPEARHEAD-1, the trial that made afami-cel the first engineered TCR T-cell therapy approved for a solid tumour.","summary":"Sandra D'Angelo was principal investigator of SPEARHEAD-1, which showed the MAGE-A4-directed TCR T-cell therapy afamitresgene autoleucel produces durable responses in synovial sarcoma and led to its 2024 approval, the first engineered T-cell therapy for a solid tumour. She also led the JAVELIN Merkel 200 trial that won avelumab approval in Merkel cell carcinoma and leads cellular therapy trials in sarcoma at MSKCC.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Angelo%20SP%5BAuthor%5D%20sarcoma%20afamitresgene"}],"tags":["sarcoma","cell-therapy","tcr-t"],"related":[],"cancers":["sarcoma","merkel-cell-carcinoma"],"sections":[],"technologies":["tcr-t"],"targets":["mage-a4"],"drugs":["afamitresgene-autoleucel"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-spearhead-1-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical Oncologist, Sarcoma and Melanoma Services, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Sarcoma","Engineered T-cell therapy","Merkel cell carcinoma","Immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=D'Angelo%20SP%5BAuthor%5D%20sarcoma%20afamitresgene"}],"papers":[{"title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1)","journal":"Lancet","year":2024,"doi":"10.1016/S0140-6736(24)00319-2"},{"title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma (JAVELIN Merkel 200)","journal":"Lancet Oncology","year":2016,"doi":"10.1016/S1470-2045(16)30364-3"},{"title":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPEARHEAD-1+afamitresgene+autoleucel+synovial+sarcoma+Lancet"}],"orcid":"0000-0002-3736-3783"},"route":"/people/sandra-dangelo/","neighbours":{"cancer":[{"id":"merkel-cell-carcinoma","kind":"cancer","name":"Merkel cell carcinoma","route":"/cancers/merkel-cell-carcinoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"technology":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"target":[{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/"}],"drug":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"paper":[{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/"}],"trial":[{"id":"checkmate-358","kind":"trial","name":"CheckMate 358","route":"/trials/checkmate-358/"}]}}